BioLineRx (BLRX) EBT Margin (2024 - 2026)
BioLineRx (BLRX) posted quarterly EBT Margin of 1152.58% for Q4 2025, down 112545.0% year-over-year from N/an in Q4 2024, and down 403.74% quarter-over-quarter from 228.81% in Q3 2025.
Powered by 
Analysis
BioLineRx (BLRX) EBT Margin (2024 - 2026) Analysis & Trends
BioLineRx's EBT Margin history runs 2 years deep, the most recent figure standing at 1152.58% for Q4 2025.
- In Q4 2025, EBT Margin fell 112545.0% year-over-year to 1152.58%; the TTM figure through Dec 2025 stood at 171.69% (down 13983.0% YoY), while the FY2025 annual figure was 171.69%, down 13983.0% from the prior year.
- EBT Margin for Q4 2025 stood at 1152.58%, down from 228.81% in the prior quarter.
- The five-year high for EBT Margin was 2010.59% in Q1 2025, with the low at 1296.05% in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.27 Bn | 131.42 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 63.45 Bn | 58.27 Bn | 1.37 Bn | 35.78% |
| 4 | Moderna | 57.73 Bn | 52.59 Bn | 52.00 Mn | -528.97% |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 18.33% |
| 7 | Alnylam Pharmaceuticals | 35.14 Bn | 31.84 Bn | 992.69 Mn | 13.77% |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 12.09% |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | -2.67% |
| 10 | BioLineRx | 6.68 Bn | 6.68 Bn | 235,000.00 | -1,099.66% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1,099.66% |
| Mar 31, 2026 | -533.75% |
| Dec 31, 2025 | -1,444.85% |
| Sep 30, 2025 | -357.38% |
| Jun 30, 2025 | -505.59% |
| Mar 31, 2025 | -657.65% |
| Dec 31, 2024 | 3.33% |
| Sep 30, 2024 | -67.33% |
| Jun 30, 2024 | -58.46% |
| Mar 31, 2024 | -48.55% |